Search results
Results from the WOW.Com Content Network
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
For premium support please call: 800-290-4726 more ways to reach us
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
For premium support please call: 800-290-4726 more ways to reach us
The StockXpert website in 2009. Until 2009, stock.xchng operated alongside its sister site, Stockxpert.Stockxpert was designed with a near-identical user interface, but functioned as a commercial microstock photography site, allowing users, through a system of online credits, to purchase and download images for a very low cost, often as low as US$1.
Vivus (VVUS) shares are trading around 15% higher Tuesday after U.S. Food and Drug Administration reviewers said its weight-loss drug Qnexa indeed helps reduce weight. Shares of rivals Orexigen ...
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses ...
For premium support please call: 800-290-4726 more ways to reach us